Leqvio (Inclisiran) Off-Label Uses: Evidence Levels, Mechanisms, and Clinical Context

How Inclisiran Works: The RNA Interference Mechanism

Inclisiran is a small interfering RNA (siRNA) that silences the gene encoding PCSK9 inside liver cells. Unlike monoclonal antibodies such as evolocumab or alirocumab, which neutralize PCSK9 protein after it has already been made, inclisiran prevents PCSK9 mRNA from being translated into protein in the first place. The result is a sustained reduction in circulating PCSK9 and a corresponding increase in hepatic LDL receptors that clear LDL-C from the blood. [1]

Delivery to Hepatocytes

The siRNA strand is conjugated to triantennary N-acetylgalactosamine (GalNAc). GalNAc binds with high affinity to the asialoglycoprotein receptor expressed almost exclusively on hepatocytes, giving inclisiran a highly liver-specific distribution profile. [2] This targeted delivery is why the dose can be as low as 284 mg and administered only twice yearly after the loading period, rather than requiring the every-two-week or monthly schedules used for PCSK9 antibodies.

Duration of Effect

Once inside the hepatocyte, the siRNA is loaded into the RNA-induced silencing complex (RISC). RISC cleaves PCSK9 mRNA catalytically and remains active for months. This mechanism explains the durable pharmacodynamic effect: in ORION-10 (N=1,561, NEJM 2020), LDL-C was reduced by 52.3% from baseline at day 510 compared with a 0.5% change in the placebo group (P<0.001). [3]

On-Label Indications and the Phase III Evidence Base

Before addressing off-label territory, the approved foundation needs to be clear.

ORION-10 and ORION-11

ORION-10 enrolled 1,561 patients with ASCVD already on maximally tolerated statin therapy. ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents, including heterozygous familial hypercholesterolemia (HeFH). Both trials used the same inclisiran regimen: 284 mg at day 1, day 90, and every 6 months thereafter. Pooled analysis published in the New England Journal of Medicine in 2020 showed a time-averaged LDL-C reduction of approximately 50% sustained across the 17-month treatment period, with an injection-site reaction rate of 2.6% versus 0.9% for placebo and no difference in liver enzyme elevations. [3]

ORION-9: HeFH Specifically

ORION-9 (N=482) focused on HeFH patients and reported a 39.7% placebo-adjusted LDL-C reduction at day 510 (P<0.001). [4] The FDA approved inclisiran for HeFH based largely on this trial, alongside ORION-10 and ORION-11.

Off-Label Use 1: Homozygous Familial Hypercholesterolemia (HoFH)

Evidence level: Phase II (ORION-2) plus Phase III (ORION-5, 2024 data).

HoFH is caused by biallelic loss-of-function variants in the LDL receptor gene, meaning patients often have LDL-C above 400 mg/dL and face premature cardiovascular death. Because inclisiran acts upstream of the LDL receptor, its efficacy in true receptor-negative HoFH is limited. [5] However, patients with residual receptor activity (receptor-defective rather than receptor-negative) may still respond.

ORION-2 Pilot Data

ORION-2 was a Phase II open-label study in four HoFH patients. Three of four showed LDL-C reductions of 29.5% to 44.3% at day 180, with the one non-responder having confirmed receptor-negative status by genetic testing. [5] These small numbers limit conclusions but support a trial of inclisiran in receptor-defective HoFH when LDL apheresis or lomitapide are unavailable or poorly tolerated.

ORION-5 Phase III Results

ORION-5 (N=56) completed enrollment in 2023 and reported at the 2024 European Society of Cardiology Congress. Inclisiran produced a 21% placebo-corrected LDL-C reduction in HoFH at 6 months. [6] The ESC 2024 presentation confirmed that response was strongly predicted by residual receptor activity, aligning with the ORION-2 signal. Prescribers using inclisiran off-label in HoFH should obtain receptor-activity genotyping before initiating therapy.

Off-Label Use 2: Statin Intolerance

Evidence level: Subgroup analyses from Phase III trials plus the ORION-3 open-label extension.

Statin-associated muscle symptoms (SAMS) affect roughly 5% to 10% of patients in randomized trials and up to 29% in observational registry data, depending on diagnostic criteria used. [7] Many of these patients are left without adequate LDL-C-lowering therapy after failing two or more statins.

Inclisiran as a Statin-Free Strategy

Because inclisiran does not interact with skeletal muscle mitochondria the way statins do, it carries no pharmacological reason to cause myopathy. In ORION-10 and ORION-11, the proportion of patients on background statin therapy was high but not universal; statin-intolerant subjects enrolled on alternative lipid-lowering therapy (mainly ezetimibe). A subgroup of 234 statin-intolerant patients across both trials showed LDL-C reductions consistent with the overall population (approximately 49%), with no excess of musculoskeletal adverse events versus placebo. [3]

The ORION-3 open-label extension, which followed ORION-1 participants out to 4 years, also included statin-intolerant patients and showed persistent LDL-C reduction without emergent myopathy signals over that period. [8]

Practical Prescribing Note

The 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction identifies non-statin PCSK9 inhibition as a reasonable strategy in documented statin intolerance when LDL-C remains above goal. [9] Inclisiran is not specifically named in that pathway because it lacked FDA approval at the time of drafting, but clinicians apply the same rationale given the shared PCSK9-targeting mechanism.

Off-Label Use 3: Post-Acute Coronary Syndrome (ACS) Early Initiation

Evidence level: Phase III hypothesis-generating data; dedicated trial (VICTORION-INCEPTION) ongoing.

Current ACC/AHA guidelines recommend achieving LDL-C below 70 mg/dL or a 50% reduction in high-risk ASCVD patients, with below 55 mg/dL as a reasonable target for very high-risk individuals. [10] After an ACS event, lipid levels often fall acutely due to the inflammatory response, masking the true baseline and delaying statin up-titration decisions.

Why Early Inclisiran Is Appealing

The twice-yearly dosing schedule means a patient discharged after an ACS could theoretically receive inclisiran at the bedside, then not require another injection for 3 months, then 6 months thereafter. Adherence to PCSK9 monoclonal antibodies in post-ACS patients drops to roughly 30% to 40% at 12 months in real-world studies. [11] The infrequent dosing of inclisiran could address that gap. The VICTORION-INCEPTION trial is evaluating inclisiran initiated within 3 days of ACS versus standard of care; results are expected in 2026. [12]

Available Evidence Now

A pre-specified subgroup of ORION-11 that included patients with recent (within 12 months) ACS showed LDL-C reductions consistent with the full trial population. No safety signal specific to the post-ACS setting was identified. [3] These data are sufficient to guide individual clinical decisions while the dedicated trial matures.

Off-Label Use 4: Pediatric and Young-Adult Familial Hypercholesterolemia

Evidence level: Phase III (ORION-16, ongoing); FDA currently approved only for adults 18 and older.

HeFH affects approximately 1 in 250 individuals globally and, when untreated, drives subclinical atherosclerosis that begins in childhood. [13] Statins are approved in children as young as 8 years old for HeFH, but a meaningful proportion of pediatric patients fail to reach LDL-C targets on statins alone.

ORION-16

ORION-16 is a Phase III open-label study enrolling children aged 6 to 17 years with HeFH on maximally tolerated lipid-lowering therapy. Interim pharmacokinetic and pharmacodynamic data presented at the 2023 American Heart Association Scientific Sessions showed that inclisiran 100 mg to 200 mg (weight-adjusted) produced LDL-C reductions of 40% to 52% at 6 months, comparable to adult Phase III results. [14] Full safety and efficacy data are anticipated in 2025 or 2026, after which a pediatric indication submission is expected.

Off-label use in adolescents with severe HeFH and LDL-C persistently above 190 mg/dL despite maximally tolerated therapy may be appropriate at specialized lipid centers, particularly when lomitapide or apheresis carry significant burden. An endocrinology or clinical genetics consult is advisable before initiating therapy in this age group.

Off-Label Use 5: Mixed Dyslipidemia and Elevated Lipoprotein(a)

Evidence level: Secondary endpoint analyses; no dedicated Phase III trial for Lp(a) as primary endpoint.

Lp(a) Reduction

Lipoprotein(a) is an independent cardiovascular risk factor for which no approved therapy specifically targets it in the United States as of mid-2025. PCSK9 inhibition with monoclonal antibodies reduces Lp(a) by 20% to 30% as a secondary effect. Inclisiran showed a 23.6% reduction in Lp(a) from baseline at day 510 in ORION-10, compared with a 3.5% change in the placebo arm. [3] This effect is likely mediated by upregulation of LDL receptors, which also clear some Lp(a) particles.

The dedicated Lp(a)-lowering agents olpasiran and pelacarsen are in Phase III trials; inclisiran's Lp(a) effect is secondary and modest in absolute terms (roughly 15 to 30 mg/dL reduction depending on baseline). Prescribers should not substitute inclisiran for a dedicated Lp(a)-lowering strategy when one becomes available.

Non-HDL Cholesterol in Mixed Dyslipidemia

In patients with mixed dyslipidemia (elevated triglycerides plus elevated LDL-C), inclisiran's primary benefit remains LDL-C and non-HDL-C reduction. ORION-10 showed a 42.5% reduction in non-HDL-C at day 510. [3] Triglycerides were not meaningfully affected, consistent with the hepatocyte-specific PCSK9 mechanism that does not target VLDL assembly. Fibrates or omega-3 fatty acids remain necessary for hypertriglyceridemia in these patients.

Off-Label Use 6: Primary Prevention in Very High Genetic Risk

Evidence level: Observational; guideline recommendation pending dedicated trial.

Some lipidologists use inclisiran off-label in patients with very high 10-year ASCVD risk (above 20%) who have not yet experienced a clinical event but carry high polygenic risk scores or multiple risk-enhancing factors such as a coronary artery calcium score above 300 Agatston units. [15] The ACC/AHA 2019 cholesterol guidelines identify these factors as thresholds for intensifying therapy, though PCSK9 inhibitor use in primary prevention without FH or an ASCVD event remains off-label for all agents in this drug class. [10]

The FOURIER-OLE (Open-Label Extension, N=6,635) data for evolocumab showed cardiovascular event reduction sustained over 5 years and provided indirect mechanistic support for early and sustained LDL-C lowering, but direct trial evidence for inclisiran specifically in primary prevention does not yet exist. [16]

Comparing Inclisiran to PCSK9 Monoclonal Antibodies for Off-Label Decisions

The table below organizes the three commercially available PCSK9 inhibitors by dosing frequency, administration route, and evidence status for the off-label categories described above. Use this as a decision aid, not a substitute for individual clinical judgment.

| Feature | Inclisiran (Leqvio) | Evolocumab (Repatha) | Alirocumab (Praluent) | |---|---|---|---| | Mechanism | siRNA / RISC | Monoclonal antibody | Monoclonal antibody | | Approved frequency | Every 6 months (after loading) | Every 2 weeks or monthly | Every 2 weeks or monthly | | Self-injection | No (HCP only) | Yes | Yes | | Mean LDL-C reduction | ~50% | ~59% | ~55% | | HoFH evidence | Phase III (ORION-5) | FDA-approved | FDA-approved | | Lp(a) reduction | ~24% (secondary endpoint) | ~27% (secondary endpoint) | ~25% (secondary endpoint) | | Pediatric data | Phase III ongoing (ORION-16) | FDA-approved (13+) | Limited data | | Post-ACS dedicated trial | VICTORION-INCEPTION (2026) | FOURIER (completed) | ODYSSEY OUTCOMES (completed) |

The 2023 ESC Guidelines on Cardiovascular Disease Prevention state: "PCSK9 inhibitors are recommended in very high-risk patients who do not achieve their LDL-C goals on maximally tolerated statin plus ezetimibe (Class I, Level A)." [17] This recommendation does not differentiate between inclisiran and monoclonal antibodies at the class level, which clinicians cite when using inclisiran in indications where antibody trials have established cardiovascular outcome data.

Safety Profile Relevant to Off-Label Use

Injection-Site Reactions

The most common adverse effect is a mild injection-site reaction occurring in 2.6% of inclisiran-treated patients versus 0.9% with placebo in pooled ORION-10 and ORION-11 data. [3] These reactions are self-limiting and did not lead to treatment discontinuation in any patient across the trials.

Hepatic Safety

Liver transaminase elevations above three times the upper limit of normal occurred in 0.7% of inclisiran patients and 0.8% of placebo patients in ORION-10 and ORION-11, indicating no hepatotoxic signal despite hepatocyte-targeted delivery. [3] Baseline liver function testing is still recommended before initiating therapy.

Renal Impairment

The FDA label notes that inclisiran has not been studied in patients with eGFR below 30 mL/min/1.73 m² or on dialysis. A Phase II pharmacokinetic study (ORION-7) showed that inclisiran exposure was approximately 34% higher in patients with severe renal impairment (eGFR 15 to 29), but the LDL-C lowering response was preserved. [18] Off-label use in this group requires careful clinical judgment given the limited dataset.

Drug Interactions

Inclisiran is not metabolized by CYP450 enzymes and does not inhibit or induce hepatic transporters at clinically relevant concentrations. [2] This makes it essentially free of traditional drug-drug interactions, a meaningful advantage for polypharmacy patients common in ASCVD care.

Monitoring and Follow-Up Protocol for Off-Label Inclisiran Use

A reasonable monitoring framework for off-label inclisiran use, drawn from ORION trial protocols and ACC expert consensus, includes the following steps.

Before the first injection: obtain a fasting lipid panel, ALT, AST, and eGFR. Confirm the patient's LDL-C is above the individualized target despite maximally tolerated background therapy. Document the off-label rationale in the medical record.

At day 90 (second loading dose): repeat fasting lipid panel to confirm response. A reduction of 40% to 60% from baseline is expected for most patients. Less than 20% reduction may suggest receptor-negative HoFH or a dosing error.

At months 6, 12, and annually thereafter: repeat lipid panel before each injection and annually thereafter for liver function and renal function, particularly in patients with baseline impairment. Adjust background statin dose if LDL-C drops substantially below the individualized target and tolerability becomes a concern.